Logo image of VCYT

VERACYTE INC (VCYT) Stock Overview

NASDAQ:VCYT - US92337F1075 - Common Stock

31.52 USD
+0.9 (+2.94%)
Last: 9/4/2025, 8:00:02 PM
31.52 USD
0 (0%)
After Hours: 9/4/2025, 8:00:02 PM

VCYT Key Statistics, Chart & Performance

Key Statistics
52 Week High47.32
52 Week Low22.61
Market Cap2.48B
Shares78.67M
Float78.21M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)0.33
PE95.52
Fwd PE37.23
Earnings (Next)11-04 2025-11-04/amc
IPO10-30 2013-10-30
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


VCYT short term performance overview.The bars show the price performance of VCYT in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 20 30

VCYT long term performance overview.The bars show the price performance of VCYT in the last 1, 2 and 3 years. 1 year 2 years 3 years 20 40 60 80

The current stock price of VCYT is 31.52 USD. In the past month the price increased by 31.5%. In the past year, price increased by 10.33%.

VERACYTE INC / VCYT Daily stock chart

VCYT Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 20.11 376.28B
AMGN AMGEN INC 12.84 150.79B
GILD GILEAD SCIENCES INC 14.57 139.93B
VRTX VERTEX PHARMACEUTICALS INC 23.43 101.77B
REGN REGENERON PHARMACEUTICALS 12.43 60.12B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 59.45B
ARGX ARGENX SE - ADR 79.14 44.90B
ONC BEONE MEDICINES LTD-ADR 6.43 37.89B
INSM INSMED INC N/A 30.13B
BNTX BIONTECH SE-ADR N/A 24.88B
NTRA NATERA INC N/A 22.86B
BIIB BIOGEN INC 8.74 20.52B

About VCYT

Company Profile

VCYT logo image Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The company is headquartered in South San Francisco, California and currently employs 824 full-time employees. The company went IPO on 2013-10-30. The firm enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The firm offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). The company has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.

Company Info

VERACYTE INC

6000 Shoreline Court, Suite 300

South San Francisco CALIFORNIA 94080 US

CEO: Bonnie H. Anderson

Employees: 824

VCYT Company Website

VCYT Investor Relations

Phone: 16502436300

VERACYTE INC / VCYT FAQ

What is the stock price of VERACYTE INC today?

The current stock price of VCYT is 31.52 USD. The price increased by 2.94% in the last trading session.


What is the ticker symbol for VERACYTE INC stock?

The exchange symbol of VERACYTE INC is VCYT and it is listed on the Nasdaq exchange.


On which exchange is VCYT stock listed?

VCYT stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for VERACYTE INC stock?

18 analysts have analysed VCYT and the average price target is 42.05 USD. This implies a price increase of 33.4% is expected in the next year compared to the current price of 31.52. Check the VERACYTE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is VERACYTE INC worth?

VERACYTE INC (VCYT) has a market capitalization of 2.48B USD. This makes VCYT a Mid Cap stock.


How many employees does VERACYTE INC have?

VERACYTE INC (VCYT) currently has 824 employees.


What are the support and resistance levels for VERACYTE INC (VCYT) stock?

VERACYTE INC (VCYT) has a support level at 30.34 and a resistance level at 31.53. Check the full technical report for a detailed analysis of VCYT support and resistance levels.


Is VERACYTE INC (VCYT) expected to grow?

The Revenue of VERACYTE INC (VCYT) is expected to grow by 12.56% in the next year. Check the estimates tab for more information on the VCYT EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy VERACYTE INC (VCYT) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does VERACYTE INC (VCYT) stock pay dividends?

VCYT does not pay a dividend.


When does VERACYTE INC (VCYT) report earnings?

VERACYTE INC (VCYT) will report earnings on 2025-11-04, after the market close.


What is the Price/Earnings (PE) ratio of VERACYTE INC (VCYT)?

The PE ratio for VERACYTE INC (VCYT) is 95.52. This is based on the reported non-GAAP earnings per share of 0.33 and the current share price of 31.52 USD. Check the full fundamental report for a full analysis of the valuation metrics for VCYT.


What is the Short Interest ratio of VERACYTE INC (VCYT) stock?

The outstanding short interest for VERACYTE INC (VCYT) is 10.43% of its float. Check the ownership tab for more information on the VCYT short interest.


VCYT Technical Analysis

ChartMill assigns a technical rating of 7 / 10 to VCYT. When comparing the yearly performance of all stocks, VCYT turns out to be only a medium performer in the overall market: it outperformed 67.92% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

VCYT Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to VCYT. While VCYT has a great health rating, its profitability is only average at the moment.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

VCYT Financial Highlights

Over the last trailing twelve months VCYT reported a non-GAAP Earnings per Share(EPS) of 0.33. The EPS increased by 144% compared to the year before.


Industry RankSector Rank
PM (TTM) 5.5%
ROA 1.96%
ROE 2.16%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-114.29%
Sales Q2Q%13.75%
EPS 1Y (TTM)144%
Revenue 1Y (TTM)19.91%

VCYT Forecast & Estimates

18 analysts have analysed VCYT and the average price target is 42.05 USD. This implies a price increase of 33.4% is expected in the next year compared to the current price of 31.52.

For the next year, analysts expect an EPS growth of 24.95% and a revenue growth 12.56% for VCYT


Analysts
Analysts83.33
Price Target42.05 (33.41%)
EPS Next Y24.95%
Revenue Next Year12.56%

VCYT Ownership

Ownership
Inst Owners107.53%
Ins Owners0.6%
Short Float %10.43%
Short Ratio5.18